Journal
JOURNAL OF CONTROLLED RELEASE
Volume 260, Issue -, Pages 46-60Publisher
ELSEVIER
DOI: 10.1016/j.jconrel.2017.05.028
Keywords
Nanomedicine; Nanoparticle; Polymer; Peg-PCL; Drug delivery; Drug targeting
Funding
- Swiss National Science Foundation (SNF) [31003A_173057]
- Swiss National Science Foundation (SNF) [31003A_173057] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
The lack of efficient therapeutic options for many severe disorders including cancer spurs demand for improved drug delivery technologies. Nanoscale drug delivery systems based on poly( ethylene glycol)-poly(epsilon-caprolactone) copolymers (PEG-PCL) represent a strategy to implement therapies with enhanced drug accumulation at the site of action and decreased off-target effects. In this review, we discuss state-of-the-art nanomedicines based on PEG-PCL that have been investigated in a preclinical setting. We summarize the various synthesis routes and different preparation methods used for the production of PEG-PCL nanoparticles. Additionally, we review physico-chemical properties including biodegradability, biocompatibility, and drug loading. Finally, we highlight recent therapeutic applications investigated in vitro and in vivo using advanced systems such as triggered release, multi-component therapies, theranostics, or gene delivery systems.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available